Focuses on developing precision oncology therapeutics targeting extrachromosomal DNA in aggressive cancers.
Boundless Bio, Inc., based in San Diego, California, is an innovative clinical-stage oncology company specializing in the development of targeted cancer therapeutics. Established in 2018 and originally known as Pretzel Therapeutics, Inc., the company rebranded to Boundless Bio, Inc. in July 2019. Boundless Bio focuses on addressing the urgent needs of patients with oncogene amplified tumors, particularly by targeting extrachromosomal DNA, a novel approach in cancer treatment.
At the forefront of its pipeline is BBI-355, the company's lead product candidate. BBI-355 is an oral inhibitor of checkpoint kinase 1 currently undergoing Phase 1/2 clinical trials in patients with oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, an oral inhibitor of ribonucleotide reductase, through Phase 1/2 clinical trials. This compound targets cancer patients with resistance gene amplifications, highlighting Boundless Bio's commitment to developing innovative therapies tailored to specific genetic profiles.
Moreover, Boundless Bio is actively pursuing the ecDTx 3 program, which focuses on targeting a kinesin involved in the cellular mechanism for segregation of extrachromosomal DNA (ecDNA). This program represents a promising avenue for potential future therapies in oncology. With a robust research and development strategy, Boundless Bio aims to deliver transformative treatments that improve outcomes for cancer patients worldwide.